The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Management of platinum-sensitive recurrent ovarian cancer (PSROC) in the era of biologics: Can ASCO’s net health benefits (NHB) inform our decisions?
 
Jonathan Foote
No Relationships to Disclose
 
Laura Jean Havrilesky
Employment - BIOVENTUS (I)
Research Funding - AstraZeneca
 
Elizabeth Lin Jewell
No Relationships to Disclose
 
Charlotte Gamble
No Relationships to Disclose
 
Jessie Ehrisman
No Relationships to Disclose
 
Gloria Broadwater
No Relationships to Disclose
 
Robert L. Coleman
Honoraria - NCCN
Consulting or Advisory Role - Clovis Oncology; DOD-CDRMP; Esperance Pharmaceuticals; Genentech/Roche; NCCN
Research Funding - Amgen; Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Johnson & Johnson; Merck; OncoMed
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Bayer; Clovis Oncology; Gradalis; Merck; Millennium; New Mexico Cancer Center; Research to Practice; Roche/Genentech; University of California, Irvine; University of Cincinnati Cancer Center; University of Miami
 
David E. Cohn
No Relationships to Disclose
 
Angeles Alvarez Secord
Honoraria - Alexion Pharmaceuticals; Astex Pharmaceuticals; AstraZeneca; Clovis Oncology; Genentech/Roche; Janssen; Tesaro
Consulting or Advisory Role - Alexion Pharmaceuticals; Astex Pharmaceuticals; AstraZeneca; Clovis Oncology; Genentech/Roche; Janssen; Tesaro
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); Morphotek (Inst); Prima BioMed (Inst); Tesaro (Inst)